Sandbox Reserved 1645
From Proteopedia
(Difference between revisions)
Line 20: | Line 20: | ||
Fibrillin-1 is a ubiquitous protein mostly expressed in muscles in its monomeric form. The monomers then polymerize to form the 10 to 12nm of diameter '''microfibrils'''. In the microfibrils the fibrillin-1 is associated to various proteins such as MAGP-1, MAGP-2, fibulin 2 and fibulin 5, elastin, versicane and LTBP-1. Those microfibrils constitute the elastic and non-elastic human connective tissues such as the dermis or the organs. This protein plays an important role in the [https://en.wikipedia.org/wiki/Cytokine cytokine] and growth factor regulation. For example, fibrillin-1 can modulate the bioavailability of TGFβ1, which is a cytokine that regulates cell survival. Changed TGFβ signaling is a significant factor in the development of certain diseases. A fibrillin-1 segment encoded by exons 44-49 triggers the release of TGFβ1 and consequently stimulates TGFβ receptor-mediated Smad2 signaling. Thereby, specific gene activation or repression can be induced. <ref>Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. ''Journal of Biological Chemistry'', volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056</ref> <ref> Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167</ref> | Fibrillin-1 is a ubiquitous protein mostly expressed in muscles in its monomeric form. The monomers then polymerize to form the 10 to 12nm of diameter '''microfibrils'''. In the microfibrils the fibrillin-1 is associated to various proteins such as MAGP-1, MAGP-2, fibulin 2 and fibulin 5, elastin, versicane and LTBP-1. Those microfibrils constitute the elastic and non-elastic human connective tissues such as the dermis or the organs. This protein plays an important role in the [https://en.wikipedia.org/wiki/Cytokine cytokine] and growth factor regulation. For example, fibrillin-1 can modulate the bioavailability of TGFβ1, which is a cytokine that regulates cell survival. Changed TGFβ signaling is a significant factor in the development of certain diseases. A fibrillin-1 segment encoded by exons 44-49 triggers the release of TGFβ1 and consequently stimulates TGFβ receptor-mediated Smad2 signaling. Thereby, specific gene activation or repression can be induced. <ref>Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. ''Journal of Biological Chemistry'', volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056</ref> <ref> Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167</ref> | ||
- | '''Fetal''' '''cardiovascular''' development : | + | '''Fetal''' '''cardiovascular''' development : |
+ | |||
The FBN-1 gene is involved in a variety of embryonic developmental programs. The microfibrils that are made from fibrillin-1 contribute to both elastic and non-elastic structures. The formation of the elastic fibers in the heart valves and the aorta require the involvement of both FBN-1 and FBN-2.It has been shown that both FBN-1 and FBN-2, along with the other components of elastic fibers, are expressed in the embryonic semilunar valves as early as 4 weeks of gestation. These molecules interact to form the elastic fibers in the ventricularis layer of the semilunar valves. Fibrillin-1 and fibrillin-2 are also crucial for the development of elastic fibers in the aorta. While expression of fibrillin-2 decreases significantly after fetal development, the expression of fibrillin-1 continues into adulthood. This supports the idea that fibrilin-2 dictates the development of early elastic fibers, while fibrillin-1 provides the structural support of mature elastic fibers. | The FBN-1 gene is involved in a variety of embryonic developmental programs. The microfibrils that are made from fibrillin-1 contribute to both elastic and non-elastic structures. The formation of the elastic fibers in the heart valves and the aorta require the involvement of both FBN-1 and FBN-2.It has been shown that both FBN-1 and FBN-2, along with the other components of elastic fibers, are expressed in the embryonic semilunar valves as early as 4 weeks of gestation. These molecules interact to form the elastic fibers in the ventricularis layer of the semilunar valves. Fibrillin-1 and fibrillin-2 are also crucial for the development of elastic fibers in the aorta. While expression of fibrillin-2 decreases significantly after fetal development, the expression of fibrillin-1 continues into adulthood. This supports the idea that fibrilin-2 dictates the development of early elastic fibers, while fibrillin-1 provides the structural support of mature elastic fibers. | ||
Line 34: | Line 35: | ||
It exists nearly 1 000 different mutations possible in this gene (<scene name='86/868178/Mutations/1'>possible mutations of amino acid residues associated with the MFS in the 3D model</scene>), but the most common one is a substitution of guanine by thymine at the 1538 nucleotide of the transcript. This type of mutation leads to a non-synonymous amino acid substitution '''Cys (cysteine) to Phe (phenylalanine)''' at the 528 position on the Fibrillin-1 gene. Because this cysteine is present in the calcium-binding domain's polypeptide chain, the epidermal growth factor-like domain's structure of FBN1 is modified by affecting the <scene name='86/868178/Disulfide_bridges/1'> disulfide bridge</scene>. The calcium cation cannot bind properly to the <scene name='86/868178/Ca_binding_site/1'> cb-EGF unit </scene> and therefore there is no stabilization of cb-EGF interdomain which causes defects in connective tissue. We can thus detect the Marfan syndrome by an increase of TGF-bp in the blood because the factors cannot bind to the protein due to a change in the binding domain's structure. <ref>E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. ''Molecular Syndormology'', volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/</ref> | It exists nearly 1 000 different mutations possible in this gene (<scene name='86/868178/Mutations/1'>possible mutations of amino acid residues associated with the MFS in the 3D model</scene>), but the most common one is a substitution of guanine by thymine at the 1538 nucleotide of the transcript. This type of mutation leads to a non-synonymous amino acid substitution '''Cys (cysteine) to Phe (phenylalanine)''' at the 528 position on the Fibrillin-1 gene. Because this cysteine is present in the calcium-binding domain's polypeptide chain, the epidermal growth factor-like domain's structure of FBN1 is modified by affecting the <scene name='86/868178/Disulfide_bridges/1'> disulfide bridge</scene>. The calcium cation cannot bind properly to the <scene name='86/868178/Ca_binding_site/1'> cb-EGF unit </scene> and therefore there is no stabilization of cb-EGF interdomain which causes defects in connective tissue. We can thus detect the Marfan syndrome by an increase of TGF-bp in the blood because the factors cannot bind to the protein due to a change in the binding domain's structure. <ref>E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. ''Molecular Syndormology'', volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/</ref> | ||
- | |||
Other diseases can occur by the substitution of other cysteines of the FBN1 transcript such as C1, C2, C3, or C4. But the consequences of these mutations are much more severe. It shows the importance of cysteine localization for the protein structure. Also, a mutation of the [https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2 TGFBR2] gene coding for the TGF-bp has been found and can cause the "Type 2 Marfan syndrome". However, not much has been discovered on the subject yet. <ref>TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2 </ref> <ref>Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/</ref> | Other diseases can occur by the substitution of other cysteines of the FBN1 transcript such as C1, C2, C3, or C4. But the consequences of these mutations are much more severe. It shows the importance of cysteine localization for the protein structure. Also, a mutation of the [https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2 TGFBR2] gene coding for the TGF-bp has been found and can cause the "Type 2 Marfan syndrome". However, not much has been discovered on the subject yet. <ref>TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2 </ref> <ref>Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/</ref> |
Revision as of 14:46, 9 January 2022
This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
Fibrillin-1
|
References
- ↑ Handford, P. A. (2000). Fibrillin-1, a calcium binding protein of extracellular matrix. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1498(2), 84–90. https://doi.org/10.1016/S0167-4889(00)00085-9
- ↑ Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343
- ↑ Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. Journal of Biological Chemistry, volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056
- ↑ Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167
- ↑ E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. Molecular Syndormology, volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/
- ↑ TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2
- ↑ Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/